NYSE:MED - Medifast Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$203.97 -3.80 (-1.83 %)
(As of 10/21/2018 10:40 AM ET)
Previous Close$203.97
Today's Range$203.97 - $212.59
52-Week Range$60.60 - $260.98
Volume326,343 shs
Average Volume281,229 shs
Market Capitalization$2.44 billion
P/E Ratio89.07
Dividend Yield0.94%
Beta0.31
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. The company sells its products through various channels, including the Internet, call centers, independent health advisors, medical professionals, franchise weight loss clinics, and direct consumer marketing. As of December 31, 2017, it operated 16 franchised Medifast weight control centers in Arizona, California, Louisiana, Minnesota, and Wisconsin; and 18 reseller locations in California, Maryland, and Pennsylvania. The company was founded in 1980 and is headquartered in Baltimore, Maryland.

Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples
SymbolNYSE:MED
CUSIP58470H10
Phone410-581-8042

Debt

Debt-to-Equity RatioN/A
Current Ratio2.53
Quick Ratio2.02

Price-To-Earnings

Trailing P/E Ratio89.07
Forward P/E Ratio45.33
P/E Growth2.27

Sales & Book Value

Annual Sales$301.56 million
Price / Sales8.08
Cash Flow$2.7345 per share
Price / Cash74.59
Book Value$9.10 per share
Price / Book22.41

Profitability

EPS (Most Recent Fiscal Year)$2.29
Net Income$27.72 million
Net Margins10.87%
Return on Equity37.25%
Return on Assets27.42%

Miscellaneous

Employees399
Outstanding Shares11,950,000
Market Cap$2.44 billion

Medifast (NYSE:MED) Frequently Asked Questions

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Thursday, September 6th. Stockholders of record on Friday, September 21st will be given a dividend of $0.48 per share on Thursday, November 8th. This represents a $1.92 annualized dividend and a dividend yield of 0.94%. The ex-dividend date is Thursday, September 20th. View Medifast's Dividend History.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) posted its quarterly earnings results on Thursday, August, 2nd. The specialty retailer reported $1.16 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.98 by $0.18. The specialty retailer earned $117.30 million during the quarter, compared to analyst estimates of $101.75 million. Medifast had a return on equity of 37.25% and a net margin of 10.87%. Medifast's revenue was up 55.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.63 earnings per share. View Medifast's Earnings History.

When is Medifast's next earnings date?

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Medifast.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided EPS guidance of $4.35-4.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.67. The company issued revenue guidance of $460-470 million, compared to the consensus revenue estimate of $398.16 million.Medifast also updated its Q3 guidance to $1.05-1.10 EPS.

What price target have analysts set for MED?

2 brokerages have issued 1 year price targets for Medifast's stock. Their forecasts range from $249.00 to $249.00. On average, they anticipate Medifast's stock price to reach $249.00 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price. View Analyst Price Targets for Medifast.

What is the consensus analysts' recommendation for Medifast?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

Who are some of Medifast's key competitors?

Who are Medifast's key executives?

Medifast's management team includes the folowing people:
  • Mr. Daniel R. Chard, CEO & Director (Age 53)
  • Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 56)
  • Mr. Bill Baker, Exec. VP of Information Technology (Age 46)
  • Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Mr. Joseph Kelleman, VP of Fin. & Corp. Controller (Age 63)

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (1.21%), Aperio Group LLC (0.32%), Chickasaw Capital Management LLC (0.29%), Nisa Investment Advisors LLC (0.09%), Seven Eight Capital LP (0.08%) and KAMES CAPITAL plc (0.07%). Company insiders that own Medifast stock include Charles P Connolly, Glenn W Welling, Jeffrey J Brown, Jeremy John Martin, Michael C Macdonald, Ralph Rushton and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

Which institutional investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including Aperio Group LLC, KAMES CAPITAL plc, Chickasaw Capital Management LLC, Strs Ohio and First Citizens Bank & Trust Co.. Company insiders that have sold Medifast company stock in the last year include Charles P Connolly, Glenn W Welling and Michael C Macdonald. View Insider Buying and Selling for Medifast.

Which institutional investors are buying Medifast stock?

MED stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Seven Eight Capital LP, Nisa Investment Advisors LLC, Mitsubishi UFJ Asset Management UK Ltd., Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have bought Medifast stock in the last two years include Glenn W Welling, Jeffrey J Brown and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $203.97.

How big of a company is Medifast?

Medifast has a market capitalization of $2.44 billion and generates $301.56 million in revenue each year. The specialty retailer earns $27.72 million in net income (profit) each year or $2.29 on an earnings per share basis. Medifast employs 399 workers across the globe.

What is Medifast's official website?

The official website for Medifast is http://www.medifast1.com.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]


MarketBeat Community Rating for Medifast (NYSE MED)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  490
MarketBeat's community ratings are surveys of what our community members think about Medifast and other stocks. Vote "Outperform" if you believe MED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Featured Article: Ex-Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel